These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Real-world comparative effectiveness of mRNA-1273 and BNT162b2 vaccines among immunocompromised adults identified in administrative claims data in the United States. Mues KE; Kirk B; Patel DA; Gelman A; Chavers LS; Talarico CA; Esposito DB; Martin D; Mansi J; Chen X; Gatto NM; Van de Velde N Vaccine; 2022 Nov; 40(47):6730-6739. PubMed ID: 36163093 [TBL] [Abstract][Full Text] [Related]
7. COVID-19 vaccine effectiveness against omicron (B.1.1.529) variant infection and hospitalisation in patients taking immunosuppressive medications: a retrospective cohort study. Risk M; Hayek SS; Schiopu E; Yuan L; Shen C; Shi X; Freed G; Zhao L Lancet Rheumatol; 2022 Nov; 4(11):e775-e784. PubMed ID: 35991760 [TBL] [Abstract][Full Text] [Related]
8. Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar. Abu-Raddad LJ; Chemaitelly H; Ayoub HH; Yassine HM; Benslimane FM; Al Khatib HA; Tang P; Hasan MR; Coyle P; Al Kanaani Z; Al Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul Rahim HF; Nasrallah GK; Al Kuwari MG; Butt AA; Al Romaihi HE; Al-Thani MH; Al Khal A; Bertollini R JAMA; 2021 Nov; 326(19):1930-1939. PubMed ID: 34724027 [TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial. Oda Y; Kumagai Y; Kanai M; Iwama Y; Okura I; Minamida T; Yagi Y; Kurosawa T; Greener B; Zhang Y; Walson JL Lancet Infect Dis; 2024 Apr; 24(4):351-360. PubMed ID: 38141632 [TBL] [Abstract][Full Text] [Related]
11. Risk of myocarditis and pericarditis after a COVID-19 mRNA vaccine booster and after COVID-19 in those with and without prior SARS-CoV-2 infection: A self-controlled case series analysis in England. Stowe J; Miller E; Andrews N; Whitaker HJ PLoS Med; 2023 Jun; 20(6):e1004245. PubMed ID: 37285378 [TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness of four COVID-19 vaccines, BNT162b2 mRNA, mRNA-1273, ChAdOx1 nCov-19 and NVX-CoV2373 against SARS-CoV-2 B.1.1.529 (Omicron) infection. Liu B; Stepien S; Qian J; Gidding H; Nicolopoulos K; Amin J; Cheng A; Macartney K Vaccine; 2023 Aug; 41(38):5587-5591. PubMed ID: 37524631 [TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of mRNA-1273 and BNT162b2 COVID-19 vaccines in immunocompromised individuals: a systematic review and meta-analysis using the GRADE framework. Wang X; Haeussler K; Spellman A; Phillips LE; Ramiller A; Bausch-Jurken MT; Sharma P; Krivelyova A; Vats S; Van de Velde N Front Immunol; 2023; 14():1204831. PubMed ID: 37771594 [TBL] [Abstract][Full Text] [Related]
14. Safety of Inactivated and mRNA COVID-19 Vaccination Among Patients Treated for Hypothyroidism: A Population-Based Cohort Study. Xiong X; Wong CKH; Au ICH; Lai FTT; Li X; Wan EYF; Chui CSL; Chan EWY; Cheng FWT; Lau KTK; Lee CH; Woo YC; Lui DTW; Wong ICK Thyroid; 2022 May; 32(5):505-514. PubMed ID: 35216517 [No Abstract] [Full Text] [Related]
15. Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex. Patone M; Mei XW; Handunnetthi L; Dixon S; Zaccardi F; Shankar-Hari M; Watkinson P; Khunti K; Harnden A; Coupland CAC; Channon KM; Mills NL; Sheikh A; Hippisley-Cox J Circulation; 2022 Sep; 146(10):743-754. PubMed ID: 35993236 [TBL] [Abstract][Full Text] [Related]
16. Factors associated with COVID-19 breakthrough infection among vaccinated patients with rheumatic diseases: A cohort study. Patel NJ; Wang X; Fu X; Kawano Y; Cook C; Vanni KMM; Qian G; Banasiak E; Kowalski E; Zhang Y; Sparks JA; Wallace ZS Semin Arthritis Rheum; 2023 Feb; 58():152108. PubMed ID: 36347211 [TBL] [Abstract][Full Text] [Related]
17. Comparative Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Against the Delta Variant. Risk M; Shen C; Hayek SS; Holevinski L; Schiopu E; Freed G; Akin C; Zhao L Clin Infect Dis; 2022 Aug; 75(1):e623-e629. PubMed ID: 35137006 [TBL] [Abstract][Full Text] [Related]
18. Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study. Tartof SY; Slezak JM; Puzniak L; Hong V; Frankland TB; Ackerson BK; Xie F; Takhar H; Ogun OA; Simmons S; Zamparo JM; Valluri SR; Jodar L; McLaughlin JM Lancet Respir Med; 2023 Dec; 11(12):1089-1100. PubMed ID: 37898148 [TBL] [Abstract][Full Text] [Related]
19. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore. Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588 [TBL] [Abstract][Full Text] [Related]
20. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study. Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]